Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial

PaperCitations, authors & open-access status

Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 139 citations, 2019 year and closed oa status.

139
Citations
2019
Year
closed
OA Status

Related on ScholarIQ

Weineng Feng
Author
The Lancet Respiratory Medicine
Journal
Lung Cancer Treatments and Mutations
Topic
Lung Cancer Treatments and Mutations
Topic
Lung Cancer Diagnosis and Treatment
Topic
Lung Cancer Research Studies
Topic
470M+ articles · free account